According to previous studies, the effect of TLS on immunotherapy such as PD-(L) 1 or PD-(L) 1 combined with cytotoxic T lymphocyte-associated protein 4 (CTLA-4) blockade is mostly positive, which has been demonstrated in multiple immunotherapy cohorts such as melanoma [5] and bladder cancer [6]. The gene discussed is CTLA4; the disease is urinary bladder carcinoma.